Ketoconazole

Generic Name: Ketoconazole

Brand Names: Extina, Ketodan, Ketoderm, Nizoral, Xolegel, Ketoconazole HRA

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₂₈Cl_₂N_₄O_₄

CAS Number: 65277-42-1

Unique Ingredient Identifier: R9400W927I

Background: Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections. It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus. Ketoconazole was first approved in an oral formulation for systemic use by...

Indication: Ketoconazole is used in the treatment or prevention of fungal infections including blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. In Europe, it is also used in the treatment of endogenous Cushing's syndrome.

Associated Conditions: Bacterial Vaginosis (BV), Blastomycosis, Candidiasis, Systemic, Chromoblastomycosis, Chronic Mucocutaneous Candidiasis (CMC), Coccidioidomycosis, Dandruff, Endogenous Cushing's Syndrome, Fungal Infections, Histoplasmosis, Paracoccidioidomycosis, Seborrheic Dermatitis, Tinea Corporis caused by Epidermophyton floccosumin, Tinea Corporis caused by Trichophyton mentagrophytes, Tinea Corporis caused by Trichophyton rubrum, Tinea Cruris caused by Epidermophyton floccosumin, Tinea Cruris caused by Trichophyton mentagrophytes, Tinea Cruris caused by Trichophyton rubrum, Tinea Pedis caused by Epidermophyton floccosumin, Tinea Pedis caused by Trichophyton mentagrophytes, Tinea Pedis caused by Trichophyton rubrum, Vaginal Candidiasis, Vulvovaginal Candidiasis, Cutaneous candidiasis, Recalcitrant Dermatophytosis, Tinea versicolor caused by Malassezia infection

Associated Therapies: -

Clinical Trials

Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation

Phase 2

Terminated

Conditions: Burns

Interventions: Procedure: Stable Isotope Infusion Study
Procedure: Collection of blood and tissues
Drug: Humatrope
Drug: Ketoconazole
Drug: Oxandrolone and propranolol combined
Drug: Placebo
Drug: Humatrope and propranolol combined
Behavioral: Exercise--Hospital supervised intensive exercise program
Behavioral: Home exercise program
Drug: Oxandrolone
Drug: Propranolol

First Posted Date: 2008-05-12

Last Posted Date: 2019-11-29

Lead Sponsor: The University of Texas Medical Branch, Galveston

Target Recruit Count: 1126

Registration Number: NCT00675714

Locations: 🇺🇸
University of Texas Medical Branch, Galveston, Texas, United States

Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle

Phase 2

Completed

Conditions: Hormonal Cycling
Prostate
Cancer

Interventions: Drug: GnRH
Drug: Ketoconazole
Drug: Bicalutamide
Drug: Testosterone transdermal gel
Drug: Estrogen transdermal patch

First Posted Date: 2008-01-07

Last Posted Date: 2016-03-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 36

Registration Number: NCT00586898

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Ketoconazole, Dexamethasone, and Hydrocortisone in Treating Patients With Prostate Cancer That Did Not Respond to Androgen-Deprivation Therapy

Not Applicable

Withdrawn

Conditions: Prostate Cancer

First Posted Date: 2007-11-16

Last Posted Date: 2013-02-01

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT00559481

Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer

Phase 1

Terminated

Conditions: Stage IV Prostate Cancer
Stage III Prostate Cancer
Prostate Adenocarcinoma
Recurrent Prostate Carcinoma

Interventions: Dietary Supplement: Calcitriol
Drug: Ketoconazole
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Therapeutic Hydrocortisone

First Posted Date: 2007-09-28

Last Posted Date: 2017-06-14

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 51

Registration Number: NCT00536991

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

A Study of the Effects of Ketoconazole Taken Orally Has on the PK Profiles of a Dose of GSK189075 in Healthy Volunteers

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus

First Posted Date: 2007-07-16

Last Posted Date: 2012-06-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 22

Registration Number: NCT00501397

Locations: 🇺🇸
GSK Investigational Site, Columbus, Ohio, United States

A Study to Assess the Safety and Interaction Between Casopitant and Ketoconazole When Taken By Healthy Adults

Phase 1

Completed

Conditions: Nausea and Vomiting, Chemotherapy-Induced

Interventions: Drug: Casopitant 150 mg
Drug: Casopitant 150 mg matching placebo
Drug: Ketoconazole
Drug: Casopitant 50 mg
Drug: Casopitant 50 mg matching placebo

First Posted Date: 2007-04-16

Last Posted Date: 2017-08-03

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 85

Registration Number: NCT00460707

Locations: 🇺🇸
GSK Investigational Site, Columbus, Ohio, United States

Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: ketoconazole
Drug: lenalidomide
Drug: therapeutic hydrocortisone

First Posted Date: 2007-04-13

Last Posted Date: 2020-07-24

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 34

Registration Number: NCT00460031

Locations: 🇺🇸
UHHS Westlake Medical Center, Cleveland, Ohio, United States
🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

and more 3 locations